Skip to content

Immunocore

US · IMCR #2968 by market cap Listed 2021
26.41 -0.22 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

Valuation each multiple against its own 5-year range

P/B ratio 3.69 Cheap vs history 4th percentile
5-year average 6.12 · #344 of 515 in Biotechnology
P/E ratio -46.78 In line with history 44th percentile
5-year average -43.81 · forward -50.27
P/S ratio 3.60 Cheap vs history 4th percentile
5-year average 13.29 · forward 3.24 · #95 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Immunocore (IMCR) 1.36B -41.27 3.25 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value28.16 Economic moatNone UncertaintyHigh

Trading 6.6% below Morningstar's fair value estimate.

Fair value

Immunocore Holdings PLC earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% premium over our quantitative fair value estimate of $28.16 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's lack of profitability decreases our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of -0.8% sits in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are overvalued.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 26.3%, a core component of valuation, falls in the bottom 30% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

Immunocore discussion 0 comments

Add a comment